"The DENT Institute is a private practice group focused on neurologic specialties and state-of-the-art neurodiagnostics. We provide comprehensive and compassionate patient care, with a team of professionals committed to showing our patients the same respect for human dignity and kindness that we would seek for our own families and loved ones. For five decades, our objective has been to provide the highest quality care for individuals in the Western New York region and beyond. Staying on the forefront of neurological advances, utilizing the latest technology and maintaining valuable partnerships with other specialized clinicians ensures that when you come to DENT you’re getting the best care possible."

During the past decade, DENT Neurologic Institute conducted 84 clinical trials. In the 10-year time frame, 84 clinical trials started and 42 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 48 clinical trials started and 24 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "DENT Neurologic Institute" #1 sponsor was "Eli Lilly and Company" with 11 trials, followed by "Allergan" with 8 trials sponsored, "H. Lundbeck A/S" with 8 trials sponsored, "Pfizer" with 8 trials sponsored and "Hoffmann-La Roche" with 8 trials sponsored. Other sponsors include 70 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "DENT Neurologic Institute" #1 collaborator was "National Institute on Aging (NIA)" with 6 trials as a collaborator, "Alzheimer's Association" with 3 trials as a collaborator, "Alzheimer's Therapeutic Research Institute" with 3 trials as a collaborator, "Neurobiological Technologies" with 3 trials as a collaborator and "Northern California Institute of Research and Education" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "DENT Neurologic Institute" are "Migraine" (22 trials), "Alzheimer's Disease" (9 trials), "Alzheimer Disease" (5 trials), "Episodic Migraine" (4 trials) and "Glioblastoma" (4 trials). Many other conditions were trialed in "DENT Neurologic Institute" in a lesser frequency.

Most popular intervention types in "DENT Neurologic Institute" are "Drug" (101 trials), "Device" (11 trials), "Other" (5 trials), "Biological" (3 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (51 trials), "Eptinezumab" (8 trials), "Galcanezumab" (6 trials), "Atogepant" (4 trials) and "Erenumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "DENT Neurologic Institute" are 116 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "DENT Neurologic Institute". undefined are not yet recruiting, 27 are recruiting, 14 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 60 completed trials in DENT Neurologic Institute, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in DENT Neurologic Institute, 4 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 62 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 7 trials that are defined as “Not Applicable".